URO ONCO

Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Therapeutic Options in High-risk Non–muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Guérin

European Urology, Volume 67, Issue 3, March 2015, Pages 359 - 360

Take Home Message

Optimal management of high-risk non–muscle-invasive bladder cancer during the current bacillus Calmette-Guérin (BCG) shortage is challenging. Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable.

Footnotes

a Department of Urology, Royal Surrey County Hospital, Guildford, UK

b Department of Urology, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain

c Headquarters, European Organisation for Research and Treatment of Cancer, Brussels, Belgium

d Department of Urology, Radboud UMC, Nijmegen, The Netherlands

Corresponding author. Department of Urology, Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, UK. Tel. +44 1483571122; Fax: +44 1256651115.